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Mirabegron, the ﬁrst b3-adrenoceptor agonist introduced for use in clinical practice, differs from anti-
muscarinic agents in terms of mechanism of action. This review discusses various perspectives on
mirabegron in terms of efﬁcacy, mechanism of action, pharmacokinetics, safety, and tolerability for
overactive bladder syndrome in studies conducted thus far. Mirabegron administered at daily doses of
25 mg, 50 mg, and 100 mg demonstrated signiﬁcant improvements in micturition frequency, urgency
incontinence, and mean volume voided/micturition as early as the ﬁrst assessment, and these were
maintained throughout the treatment course. Mirabegron seemed well tolerated. The most common
adverse events observed with mirabegron in clinical trials were hypertension, nasopharyngitis, and
urinary tract infection. The incidence of dry mouth was similar to that with placebo, between 3- and 5-
fold lower than with 4 mg tolterodine extended release. Considering that dry mouth is the most both-
ersome adverse event associated with antimuscarinic drugs and often a reason for treatment discon-
tinuation, mirabegron may be a valuable treatment option for these patients. The beneﬁt of mirabegron
(at doses of 50 mg and 100 mg) was also evident in elderly patients and in both treatment-naive patients
and those who previously discontinued antimuscarinic therapy. Mirabegron can also be used in com-
bination with antimuscarinics or in addition to alpha blockers. Mirabegron may quickly become a
standard treatment of overactive bladder syndrome.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Overactive bladder (OAB) syndrome is a highly prevalent con-
dition characterized by the presence of urinary urgency, with or
without urgency urinary incontinence, usually with frequency and
nocturia.1 Epidemiological data suggest that OAB syndrome is
present in about 12% of all adult men and women, although prev-
alence rates increase with aging in both sexes.2 In Asia, the preva-
lence among adult men in India, Indonesia, Malaysia, Pakistan,
Philippines, Singapore, Korea, Taiwan, China, Hong Kong, and
Thailand has been estimated as 29.9%.3 Antimuscarinics are the
standard ﬁrst-line drug therapy for OAB syndrome.4,5 They have
been suggested to reduce detrusor activity and improve bladder
capacity via additional mechanisms, including direct inhibition ofrtment of Surgery, Cardinal
ian District, New Taipei City
ciation. Published by Elsevier Taiwbladder afferent signaling at the level of the urothelium and sub-
urothelium.6 However, some patients have a suboptimal response
to antimuscarinics or may experience adverse effects such as dry
mouth or constipation.7,8 Therefore, a high proportion of patients
discontinue antimuscarinic therapy, with fewer than 25% remain-
ing on treatment at 1 year.9
A b3 adrenoceptor agonist acts on a different molecular
pathway. b3-Adrenoceptors are the predominant b-receptor sub-
type in the urinary bladder10 and are known to promote urine
storage in the bladder by inducing detrusor relaxation in animal
and human bladders.11e13 Mirabegron is the ﬁrst b3-adrenoceptor
agonist14 to have been approved for the treatment of OAB syn-
drome (in Japan, the United States, Europe, Canada, Australia, Hong
Kong, Korea, and Taiwan). Product labeling differs between coun-
tries, with a recommended starting dose of 25 mg once daily (QD)
in the United States and Canada (Myrbetriq, Astellas Pharma Inc.,
Northbrook, IL, USA), with an option to increase to 50 mg, and a
recommended dose of 50 mg QD in Japan (Betanis, Astellas Pharma
Inc., Chuo-ku, Tokyo, Japan) and Europe (Betmiga, Astellas Pharma
BV, Leiden, The Netherlands), with the 25-mg dose reserved foran LLC. Open access under CC BY-NC-ND license.
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C.-H. Kuei et al. / Urological Science 26 (2015) 17e2318special populations (e.g., those with severe renal impairment or
moderate hepatic impairment).15 In Taiwan, the recommended
starting dose was 25 mg QD, with an option to increase to 50 mg.
Mirabegron has been studied extensively over approximately 10
years, and > 5500 patients with OAB syndrome have received mir-
abegron in Phase II and III studies.15 Most of the studies shared
similar designs, although the doses of mirabegron and inclusion of
placebo and/or an active control arm with 4-mg tolterodine
extended release (ER) varied across trials (Table 1). Chapple et al16
reported a proof-of-concept, randomized, double-blind, parallel-
group, Phase IIA study [BLOSSOM (Study 178-CL-008;
NCT01604928)] at doses of 100 mg or 150 mg twice daily (BID),
placebo (BID), or 4 mg tolterodine ER QD for 4 weeks. Following
the BLOSSOM trial, Chapple et al17 conducted a 12-week European
Phase IIB dose-ranging study [DRAGON (Study 178-CL-044;
NCT00337090)] at doses of 25 mg, 50 mg, 100 mg, and 200 mg QD
versus placebo. Three pivotal, large-scale, 12-week, multicenter,
randomized, double-blind, parallel-group, Phase III studies con-
ducted in Europe, Australia, and North America featured the copri-
mary end points of change from baseline to ﬁnal follow-up visit in a
mean number of micturitions in 24 hours and mean number of in-
continence episodes in 24 hours. Khullar et al,18 Nitti et al,19 and
Herschorn et al20 reported on results from Europe and Australia
[SCORPIO (Study 178-CL-046; NCT00689104)], North America
[ARIES (Study 178-CL-047; NCT00662909)], and Europe and North
America [CAPRICORN (Study 178-CL-074; NCT00912964)], respec-
tively. Long-term safety and tolerability data on mirabegron were
obtained from a 1-year, randomized, Phase III trial [NCT00688688;
Study 049; TAURUS (Study 178-CL-049; NCT00688688)].21 Recently,
Yamaguchi et al22 andKuoet al23 also reported the results of Phase III
studies using mirabegron (50 mg, QD) in Japan and Asia.[1
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.2. Mechanism of action
Detrusor relaxation is primarily mediated by the cyclic adeno-
sine monophosphate pathway, activated via the binding of
norepinephrine to b-adrenoceptors. Three subtypes of b-adreno-
ceptors (b1, b2, and b3) have been identiﬁed in the detrusor muscle
and urothelium.24,25 b3-Adrenoceptors account for > 95% of all
b-adrenoceptorsmRNA in the human bladder and are thought to be
the main b-adrenoceptors mediating human detrusor relaxa-
tion.10,11 Stimulation of b3-adrenoceptors elicits direct relaxation of
detrusor smooth muscle; the underlying cellular mechanisms are
not fully clear but may involve activation of adenylyl cyclase and
subsequent increases in the intracellular levels of cyclic adenosine
phosphate and Ca channels.26 Mirabegron shows high intrinsic
activity for b3-adrenoceptors and very low intrinsic activity for b1
and b2 adrenoceptors. In Chinese hamster ovary cells that express
human b3-adrenoceptors, the half-maximal effective concentration
(EC50) value was 22.4nM compared with EC50 values > 10,000nM
for b1 and b2 adrenoceptors.14 Mirabegron improves the storage
capacity of the bladder without impairing bladder contraction
during voiding.Ta
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Mirabegron is rapidly absorbed after oral administration and
circulates in plasma in its unchanged form, its glucuronic acid
conjugates, and other metabolites, which are pharmacologically
inactive. Mirabegron is metabolized in the liver via multiple path-
ways and is recovered in urine (55%) and feces (34%) mainly in its
unchanged form.27 Because mirabegron is metabolized by cyto-
chrome P450 (CYP) 3A428 and, to a minor extent, by CYP2D6 in
humans,29 it may be subject to clinically relevant drugedrug
C.-H. Kuei et al. / Urological Science 26 (2015) 17e23 19interactions and should therefore be used with caution in patients
who are taking ketoconozole or other potent CYP3A inhibitors.
4. Clinical efﬁcacy
In the proof-of-concept BLOSSOM study,16 mirabegron (100 mg
and 150 mg, BID) showed statistically signiﬁcant improvement
versus placebo in the mean change of micturition frequency from
baseline to the ﬁnal visit (p < 0.01). The mean volume voided
(MVV)/micturition was dose-dependently increased in the mir-
abegron groups, with a signiﬁcant difference between the placebo
group and 150-mg mirabegron group (p < 0.05). Urgency episodes
in 24 hours decreased signiﬁcantly for both mirabegron groups
(p < 0.05). Statistically signiﬁcant improvements in changes in in-
continence episodes, urgency incontinence [urge urinary inconti-
nence (UUI)] episodes, and nocturia episodes were also observed
for 100 mg mirabegron (p < 0.05). In the dose-ranging DRAGON
study, the primary efﬁcacy results showed dose-dependent de-
creases in mean number of micturitions in 24 hours, which were
statistically signiﬁcantly different between the placebo and 50-,
100-, and 200-mg mirabegron groups (p < 0.05, Table 2). In addi-
tion, from baseline to ﬁnal follow-up visit, the mean improvements
in MVV, incontinence episodes, UUI episodes, urgency episodes,
level of urgency, and nocturia episodes were statistically
signiﬁcant.17Table 2
Primary efﬁcacy end points (changes from baseline to ﬁnal follow-up visit).a
M
25 mg 5
DRAGON [17]
Micturition/24 h n ¼ 167 n
Adjusted mean (95% CI) 1.9 (1.0 to 0.1) 
Treatment difference vs. placebo (SE) 0.5 (0.3) 
SCORPIO [18]
Micturition/24 h n
Adjusted mean (SE) 
Treatment difference vs. placebo (SE) 
Incontinence episodes/24 h n
Adjusted mean (SE) 
Treatment difference vs. placebo (SE) 
ARIES [19]
Micturition/24 h n
Adjusted mean (SE) 
Treatment difference vs. placebo (SE) 
Incontinence episodes/24 h n
Adjusted mean (SE) 
Treatment difference vs. placebo (SE) 
CAPRICORN [20]
Micturition/24 h n ¼ 410 n
Adjust mean (SE) 1.7 (0.1) 
Treatment difference vs. placebo (SE) 0.5 (0.2)* 
Incontinence episodes/24 h n ¼ 254 n
Adjust mean (SE) 1.4 (0.1) 
Treatment difference vs. placebo (SE) 0.4 (0.2)* 
TAURUS [21]
Micturition/24 h n
Adjust mean (SE) 
Incontinence episodes/24 h n
Adjust mean (SE) 
Treatment difference vs. placebo (SE)
Asian's study [23]
Micturition/24 h n
Treatment difference vs. placebo (95% CIs) 
Incontinence episodes/24 h n
Treatment difference vs. placebo (SE) 
*p < 0.05.
CI ¼ conﬁdence interval; ER ¼ extended release; SE ¼ standard error.
a ARIES study, 178-CL-047 (NCT00662909); Asian study, (NCT01043666); CAPRICORN
SCORPIO study, 178-CL-046 (NCT00689104); TAURUS study, 178-CL-049 (NCT00688688For SCORPIO, ARIES, and CAPRICORN studies, statistically sig-
niﬁcant improvements were found for both doses of mirabegron
compared with placebo in both the coprimary end points (p < 0.05;
Table 2). In the SCORPIO study, statistically signiﬁcant improve-
ments in MVV and mean number of UUI episodes in 24 hours were
found from baseline to ﬁnal follow-up visit (p < 0.05).18 These
secondary efﬁcacy results were conﬁrmed by ARIES, which showed
statistically signiﬁcant improvements in MVV, level of urgency
number of UUI episodes, urgency episodes, and nocturia episodes in
24 hours from baseline to ﬁnal visit, and in number of incontinence
episodes and micturitions in 24 hours from baseline to Week 4 for
both mirabegron groups compared with the placebo group (all
p < 0.05).19 With regard to observations at earlier time points in the
CAPRICORN study,20 compared with placebo, 50 mg mirabegron
demonstrated signiﬁcantly greater improvements at Week 4 in
mean number of incontinence episodes in 24 hours (p < 0.001).
Both mirabegron groups demonstrated statistically signiﬁcant im-
provements at Week 8 in mean number of incontinence episodes
and micturitions in 24 hours compared with the placebo group.
Compared with placebo, 50 mg mirabegron also demonstrated
statistically signiﬁcant improvements at these time points in mean
level of urgency, number of UUI episodes in 24 hours, and urgency
episodes (Grade 3 or 4). The 25-mg mirabegron group demon-
strated numerically greater improvements on the three urgency
assessments than did the placebo group. However, reduction fromirabegron (daily dose) Tolterodine ER 4 mg
0 mg 100 mg
¼ 167 n ¼ 168 n ¼ 85
2.1 (12 to 0.1) 2.1 (12 to 0.1) 2.0 (12 to 0.2)
0.6 (0.3)* 0.7 (0.3)* 0.5 (0.3)
¼ 473 n ¼ 478 n ¼ 475
1.9 (0.1) 1.8 (0.1) 1.6 (0.1)
0.6 (0.2)* 0.4 (0.2)* 0.3 (0.2)
¼ 293 n ¼ 281 n ¼ 300
1.6 (0.1) 1.5 (0.1) 1.3 (0.1)
0.4 (0.2)* 0.3 (0.2)* 0.1 (0.2)
¼ 425 n ¼ 412
1.7 (0.1) 1.8 (0.1)
0.6 (0.2)* 0.7 (0.2)*
¼ 312 n ¼ 295
1.5 (0.1) 1.6 (0.1)
0.3 (0.2)* 0.5 (0.2)*
¼ 426
1.6 (0.1)
0.4 (0.2)*
¼ 257
1.4 (0.1)
0.4 (0.2)*
¼ 789 n ¼ 802 n ¼ 791
1.3 (0.1) 1.4 (0.1) 1.4 (0.1)
¼ 479 n ¼ 483 n ¼ 488
1.0 (0.1) 1.2 (0.1) 1.3 (0.1)
¼ 338 n ¼ 333
0.57 (1.04, 0.08)* 0.03 (0.44, 0.51)
¼ 136 n ¼ 137
0.11 (0.58, 0.37) 0.07 (0.54, 0.41)
study, 178-CL-074 (NCT00912964); DRAGON study, 178-CL-044 (NCT00337090);
).
C.-H. Kuei et al. / Urological Science 26 (2015) 17e2320baseline to Week 4 and Week 8 in the mean UUI episodes in 24
hourswas the only urgency assessmentwith statistical signiﬁcance.
Nitti et al30 reported primary and secondary efﬁcacy data from a
prespeciﬁed pooled analysis of these three studies. In the pooled
efﬁcacy analysis, 2542 patients were included. Additional second-
ary end points included two responder analyses based on inconti-
nence episodes at the ﬁnal visit [patients who were incontinent at
baseline who recorded zero incontinence episodes at the ﬁnal visit
(dry rate) and patients with a 50% decrease from baseline in mean
number of incontinence episodes in 24 hours] and a post hoc
analysis of the proportion of patients with < 8 micturitions in 24
hours at the ﬁnal follow-up visit. In all cases, the percentages of
patients were signiﬁcantly higher in the 50- and 100-mg mirabe-
gron groups than in the placebo group (p < 0.05).
Although the TAURUS study was not designed to demonstrate a
statistically signiﬁcant difference in efﬁcacy between the treatment
groups, the 50- and 100-mg mirabegron groups showed numerical
improvements from Month 1 to Month 12 in mean number of
micturitions in 24 hours, incontinence episodes in 24 hours, and
MVV/micturition.21 At the ﬁnal visit, the percentage of responders
for zero incontinence episodes was 43.4% and 45.8% in the 50- and
100-mg mirabegron groups, respectively. The percentages of re-
sponders with 50% decrease from baseline in mean number of in-
continence episodes in 24 hours was 63.7% and 66.3%, respectively.
In addition, the efﬁcacy proﬁle of 50 mgmirabegron also appears to
be maintained over 12 months.31
In a study in Japan,22 mirabegron was signiﬁcantly superior to
placebo in terms of mean change from baseline to ﬁnal follow-up
visit in number of micturitions in 24 hours (1.67 vs. 0.86;
p < 0.001) and mean change in number of urgency episodes in 24
hours (1.85 vs. 1.37; p ¼ 0.025), incontinence episodes in
24 hours (1.12 vs. 0.66; p ¼ 0.003), urgency incontinence epi-
sodes in 24 hours (1.01 vs.0.60; p ¼ 0.008), and volume voided/
micturition (24.30 mL vs. 9.715 mL; p < 0.001). However, in an
Asian study,23 only statistically signiﬁcant improvement in mean
number of micturitions in 24 hours was observed with 50 mg
mirabegron compared with placebo at all time points (p < 0.05),
including the ﬁnal follow-up visit (0.57, p ¼ 0.019). No signiﬁcant
difference in improvement from baseline to ﬁnal visit in any of the
secondary outcome measures, except volume voided per micturi-
tion, was observed between the treatment groups.
In a systematic literature review and mixed treatment com-
parison between 50 mg mirabegron and antimuscarinics in pa-
tients with OAB syndrome, the Bayesian mixed treatment
comparisons showed that 50 mg mirabegron was as efﬁcacious as
antimuscarinics in reducing the frequency of micturition inconti-
nence and UUI episodes, with the exception of 10 mg solifenacin,Table 3
Adverse events (AEs) associated with antimuscarinics: incidence with mirabegron, place
SCORPIO, ARIES, and CAPRICORN studies [15].a
AEs Placebo
(n ¼ 1380), n (%)
Mirabegron
25 mg (n ¼ 432),
n (%)
50 mg (n ¼ 1375),
n (%)
100 mg (
n (%)
Any AE 658 (47.7) 210 (48.6) 647 (47.1) 402 (43.3
Dry mouth 29 (2.1) 8 (1.9) 23 (1.7) 23 (2.5)
Pruritis 5 (0.4) 1 (0.2) 3 (0.2) 3 (0.3)
Constipation 20 (1.4) 7 (1.6) 22 (1.6) 15 (1.6)
Erythema 2 (0.1) 0 1 (0.1) 1 (0.1)
Blurred vision 3 (0.2) 0 2 (0.1) 4 (0.4)
Fatigue 14 (1.0) 6 (1.4) 17 (1.2) 7 (0.8)
Urinary retention 6 (0.4) 0 1 (0.1) 0
a ARIES study, 178-CL-047 (NCT00662909); CAPRICORN study, 178-CL-074 (NCT009
(NCT00688688).which was more efﬁcacious than 50 mg mirabegron in improving
micturition frequency and UUI frequency.32 In another study that
evaluated the effects of treatment for OAB on health-related quality
of life (HR-QoL), mirabegron showed quicker and superior
improvement in HR-QoL than 4 mg tolterodine ER.33
5. Safety and tolerability
5.1. General safety and tolerability
In general, treatment with mirabegronwas well tolerated. In the
BLOSSOM study, treatment-emergent adverse events (TEAEs) were
reported, with an incidence of 18.5% and 24.6% in the 100- and 150-
mg mirabegron BID groups, respectively, compared with 24.2% in
the placebo group and 26.6% in the 4-mg tolterodine ER group.16
The rates of discontinuation owing to adverse events (AEs) were
low at 4.6% (100 mg mirabegron, BID), 7.7% (150 mg mirabegron,
BID), 1.5% (placebo), and 3.1% (4 mg tolterodine ER, QD). In the
DRAGON study, the incidence of TEAEs was comparable between
the mirabegron and placebo groups (20.1%, 22.5%, 21.4%, and 22.2%
in the 25-, 50-, 100-, and 200-mg mirabegron groups, respectively,
vs. 15.4% in the placebo group).17 Discontinuation rate due to AEs
was low at 2.4e5.3% in the mirabegron groups, 3.0% in the placebo
group, and 1.2% in the tolterodine ER group.
Pooled safety data from the SCORPIO, ARIES, and CAPRICORN
studies showed that the overall incidence of TEAEs was similar
across treatment groups and that no evidence of a doseeresponse
relationship was found across the mirabegron treatment groups for
overall incidence rates of TEAEs (Table 3).30,34,35 The most common
drug-related TEAEs in the mirabegron groups were hypertension
and headache, which occurred at a similar incidence rate in the
placebo and tolterodine groups, and dry mouth, which occurred at
a similar incidence rate in the mirabegron and placebo groups but
occurred 5-fold more frequently in the tolterodine group (2.0% in
the total mirabegron groups vs. 2.1% in the placebo group and 10.1%
in the tolterodine group).
In the 12-month TAURUS study, the incidence of TEAEs was
similar across the 50-mg mirabegron (59.7%), 100-mg mirabegron
(61.3%), and 4-mg tolterodine ER groups (62.6%).21 The most
frequent TEAEs included hypertension, dry mouth, constipation,
and headache, occurring at similar incidence rates across the
treatment groups, except for dry mouth, which was highest in the
tolterodine group (8.6%; 50- and 100-mg mirabegron groups, 2.8%
and 2.3%, respectively). Discontinuation owing to AEs was compa-
rable across the treatment groups, occurring in only 6.4%, 5.9%, and
6.0% of the patients who were receiving 50-, 100-, and 4-mg tol-
terodine ER, respectively.bo, and 4 mg tolterodine extended release (ER) in a pooled analysis of data from the
Total mirabegron
(n ¼ 2736), n (%)
Tolterodine ER 4 mg
(n ¼ 495), n (%)
Systemic review and
meta-analysis51
n ¼ 929), Antimuscarinic
therapy (%)
Placebo (%)
) 1259 (46.0) 231 (46.7) 53.4 39.9
54 (2.0) 50 (10.1) 29.6 7.9
7 (0.3) 7 (1.4) 15.4 5.2
44 (1.6) 10 (2.0) 7.7 3.9
2 (0.1) 1 (0.2) 6.9 2.0
6 (0.2) 0 3.8 2.6
30 (1.1) 9 (1.8) 1.6 0.6
1 (<0.1) 3 (0.6) 1.1 0.2
12964); SCORPIO study, 178-CL-046 (NCT00689104); TAURUS study, 178-CL-049
C.-H. Kuei et al. / Urological Science 26 (2015) 17e23 21None of the patients in the BLOSSOM study16 reported serious
AEs (SAEs), and SAEs were reported in < 2% of patients across
treatment groups in the DRAGON study.17 In the 12-month TAURUS
study, the incidence of treatment-emergent SAEs was similar be-
tween the 50-mg mirabegron (5.2%), 100-mg mirabegron (6.2%),
and 4-mg tolterodine ER groups (5.4%). Most SAEs were considered
unrelated to the study drug.21 The incidence of AEs in the mir-
abegron group was similar to that in the placebo group, and most
AEs were mild in both the Japanese22 and Asian studies.23
In a systematic literature review and mixed treatment com-
parison between 50-mg mirabegron and antimuscarinics in pa-
tients with OAB syndrome, 50-mg mirabegron showed an
incidence of dry mouth similar to that with placebo and signiﬁ-
cantly lower than that with all the included antimuscarinics.32
Although antimuscarinics may increase ocular pressure, which
makes them unsuitable for treatment of patients with uncontrolled
narrow angle glaucoma, oral intake of 100-mg mirabegron (QD) for
8 weeks did not increase intraocular pressure in healthy volunteers
and was generally safe and well tolerated.36
5.2. Cardiovascular safety
A randomized, placebo, and active-controlled (400 mg moxi-
ﬂoxacin), parallel, crossover heart rate-corrected QT interval (QT/
QTc) study in 352 healthy individuals found that mirabegron at a
dose of 50- or 100-mg did not cause QTc prolongation.37 Only at a
supratherapeutic dose (200 mg) was the QTc interval prolonged in
women. However, these ﬁndings were not replicated in other large
clinical studies. Electrocardiogram ﬁndings revealed no overt
trends in central tendency or categorical outliers for QTc interval
assessment across treatment groups.15 Data from healthy volun-
teers showed a mirabegron-related doseeresponse elevation in
heart rates of 6.7 bpm, 11 bpm, and 17 bpm for the 50-, 100-, and
200-mg dose groups, respectively, and 24-hour mean increases in
systolic blood pressure of 3.0 mmHg, 5.5 mmHg, and 9.7 mmHg,
respectively, compared with the placebo group.37 However, in the
pooled Phase III clinical studies with a large number of patients, the
change in mean pulse rate for mirabegron was approximately 1
bpm compared with placebo, similar to the change from baseline
pulse rate described for antimuscarinics.15 In the pooled population
from the SCORPIO, ARIES, and CAPRICORN,30 and 12-month
TAURUS study,21 mirabegron was associated with an increase of 
1 mmHg in blood pressure compared with placebo. The incidence
of hypertension was also similar between the total mirabegron,
placebo, and 4-mg tolterodine ER groups.15
Although the observed cardiovascular effects were minimal and
not clinically relevant as far as we know from the large number of
patients included in randomized clinical trials, even such minimal
modiﬁcations in heart rate and blood pressure could have some
impact in individuals with signiﬁcant cardiovascular risk factors or
concomitant cardiovascular disease, as often found in elderly pa-
tients with OAB syndrome. Postmarketing pharmacovigilance will
be of extraordinary importance because we are evaluating a totally
new class of drug.38
5.3. Urinary retention
No clinically relevant effects on postvoid residual (PVR) volume
were reported in the BLOSSOM study.16 When the safety set for the
pooled population from the SCORPIO, ARIES, and CAPRICORN
studies were analyzed (n ¼ 4611 patients), the mean change from
baseline to ﬁnal visit in PVR volume was unremarkable across
treatment groups.30 No episodes of acute urinary retention were
reported in the DRAGON study.17 In the pooled population, the
incidence of urinary retention was low and even lower inmirabegron-treated patients than in placebo or tolterodine-treated
patients [total mirabegron, n¼ 1 (< 0.1%); placebo, n¼ 7 (0.5%); and
tolterodine, n ¼ 3 (0.6%)].30 In the 12-month TAURUS study, one
patient each in the 50- and 100-mg mirabegron groups and three
patients in the 4-mg tolterodine ER group reported urinary reten-
tion (confounded by a prior lumbar stenosis procedure in the 100-
mg mirabegron group). Acute urinary retention requiring cathe-
terization was reported by none, one, and one patient in the 50-,
100-, and 4-mg tolterodine ER groups, respectively.21
In another urodynamic study of mirabegron inmales with lower
urinary tract symptoms (LUTS) and bladder outlet obstruction, 12
weeks of treatment with 50- and 100-mg mirabegron did not
adversely affect voiding urodynamics (Qmax and PdetQmax)
compared with placebo in male patients with LUTS and signiﬁcant
bladder outlet obstruction.39
6. Perspectives
Although the therapeutic effect of mirabegron was statistically
signiﬁcant compared with placebo, the observed beneﬁt on efﬁcacy
endpointswas not remarkable. It can be assumed that inmost of the
patients, symptoms will be only partially improved, as with anti-
muscarinics. Despite that,mirabegronmay represent a revolution in
the treatment of patients with OAB syndrome, and it is supposed to
quickly become a standard treatment of OAB syndrome because of
its favorable AE proﬁle. However, the available data cannot allow us
to identify the most appropriate role for the drug as either ﬁrst- or
second-line therapy after antimuscarinics, and randomized clinical
trials that aim to identify the best sequences of treatments are
warranted,38 as well as cost-effectiveness analyses.40
The availability for the ﬁrst time of a second class of oral drug
may open the door to the combination of mirabegron and an anti-
cholinergic, which, considering the different mechanisms of action,
might be effective. Abrams et al41 conducted a randomized, double-
blind, dose-ranging, Phase II study to evaluate the efﬁcacyand safety
results of combination treatment with mirabegron and solifenacin
in patients with OAB syndrome (Symphony).41 In one of the 12
groups, 1306 patients (66.4% female) were randomized to 12 weeks
of treatment as follows: six combination groups (2.5-, 5-, or 10-mg
solifenacin plus 25- or 50-mg mirabegron), ﬁve monotherapy
groups (2.5-, 5-, or 10-mg solifenacin, or 25- or 50-mgmirabegron),
or placebo. All the combinations with 5- or 10-mg solifenacin
signiﬁcantly improved the MVV/micturition, with adjusted differ-
ences ranging from 18.0 mL to 26.3 mL, compared with 5 mg sol-
ifenacin monotherapy. Compared with 5 mg solifenacin, three
combination groups signiﬁcantly reduced micturition frequency,
ranging from 0.80 to 0.98. Five of six combinations signiﬁcantly
reduced urgency episodes, ranging from 0.98 to 1.37, compared
with 5 mg solifenacin. No dose-related trends in TEAEs, blood
pressure, pulse rate, PVR volume, or laboratory or electrocardiogram
parameters were observed between the combination and mono-
therapy groups, although the incidence of constipationwas slightly
increased with the combination therapy. They concluded that
combination therapy with solifenacin/mirabegron signiﬁcantly
improvedMVV, micturition frequency, and urgency compared with
5 mg solifenacin monotherapy. All the combinations were well
tolerated, with no important additional safety ﬁndings compared
with the monotherapy or placebo.
In addition, considering the high prevalence of storage symp-
toms in men with voiding LUTS that are suggestive of benign
prostatic obstruction (BPO), mirabegron might also be a valuable
option in combination or sequential treatments with alpha-
blockers, considering the lack of effects on PVR volume. Ichihara
et al42 conducted a randomized controlled study to evaluate the
efﬁcacy of tamsulosin monotherapy and its combination with
C.-H. Kuei et al. / Urological Science 26 (2015) 17e2322mirabegron in patients with OAB syndrome induced by BPO. Pa-
tients with BPO with urinary urgency at least once per week and a
total OAB symptom score  3 points after  8 weeks of treatment
with tamsulosin were enrolled. The change in the total OAB
symptom score during the treatment period was signiﬁcantly
greater in the combination group than in the monotherapy group
(2.21 vs. 0.87, p ¼ 0.012). The changes in the scores for urinary
urgency and daytime frequency, and the International Prostate
Symptom Score storage symptom subscore and QoL for 8 weeks
were signiﬁcantly greater in the combination group. The change in
PVR was signiﬁcantly greater in the combination group. Although
six patients developed AEs in the combination group, urinary
retention was observed in only one patient. They concluded that
combined treatment with tamsulosin and mirabegron is effective
and safe for patients with BPO who have persistent OAB symptoms
despite tamsulosin monotherapy. In another study that evaluated
the potential pharmacokinetic and cardiovascular interactions of
the combination of tamsulosin and mirabegron,43 the observed
pharmacokinetic interactions upon the addition of mirabegron or
tamsulosin to existing tamsulosin or mirabegron therapy did not
cause clinically relevant changes in cardiovascular safety or safety
proﬁles.
Otsuki et al44 conducted a prospective study to investigate the
safety and efﬁcacy of 50 mg mirabegron for patients with OAB
syndrome unresponsive to antimuscarinic agents or related to
BPO.44 One hundred twenty-four patients (72% male) were
assigned to either a control or an 8-week mirabegron treatment
group. Mirabegron signiﬁcantly decreased the total OAB symptom
score, daytime and nighttime micturition frequencies, urinary ur-
gency, urgency incontinence score, and International Prostrate
Symptom Score-QoL index in patients with newly diagnosed OAB
syndrome. In addition, PVR urine volume did not signiﬁcantly
change throughout the study period. No signiﬁcant difference was
found between response and PVR volume in men and women. The
authors concluded that mirabegron is safe and effective for OAB
syndrome refractory to antimuscarinics. In another post hoc sub-
group analysis, mirabegron provided treatment beneﬁts both in
patients with OAB syndrome who were antimuscarinic treatment-
naive and in patients who had received prior antimuscarinic
treatment.45
Further analyses were performed to identify suitable candi-
dates for mirabegron therapy. A post hoc analysis of pooled data
from three randomized Phase III trials showed that the treatment
effect for incontinence and urgency episodes increased with
increasing severity of incontinence at baseline.46 Another pro-
spective subanalyses of individual and pooled efﬁcacy and toler-
ability data from three 12-week, randomized, Phase III trials, and
of tolerability data from a 1-year safety trial were conducted in
order to evaluate the efﬁcacy and tolerability of mirabegron in
subgroups of patients aged  65 years and  75 years.47 In both
age groups, hypertension and urinary tract infection were among
the most common TEAEs. The incidence of dry mouth, a typical
anticholinergic TEAE, was up to 6-fold higher among the older
patients randomized to receive tolterodine than among those
randomized to receive any dose of mirabegron. These analyses
have demonstrated the efﬁcacy of mirabegron over 12 weeks and
the tolerability of mirabegron over 12 weeks and 1 year in patients
with OAB syndrome aged  65 years and  75 years, supporting
mirabegron as a therapeutic option for older patients with OAB
syndrome.
Patients with neurogenic LUTS may also beneﬁt from mirabe-
gron therapy; however, such trials are awaited. Trials on head-to-
head comparisons with solifenacin are also awaited. In addition,
other selective b3-adrenoceptor agonists are currently in develop-
ment. Results of Phase II trials have been reported for solabegron inincontinent female patients with OAB syndrome,48 and preclinical
studies have been reported for ritobegron49,50 and TRK-380.51
7. Conclusion
Mirabegron is the ﬁrst in a new class of agents and is the ﬁrst
new class of oral pharmacological therapy for OAB syndrome for
more than 30 years. Although the inclusion and exclusion criteria in
these trials limit the ability to extrapolate the results beyond the
populations studied, the outcomes of the use of this therapy both
alone and in combination with other pharmacotherapeutic agents
in real-life clinical practice are awaited with interest.
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